Aspirin 81mg for Pre-eclampsia

"Confirmed, the clinical trial is actively in recruitment mode. Initially posted on May 28th 2021, the study's details were recently revised as of June 25th 2021 via data hosted by clinicaltrials.gov."

"The initial research on Aspirin 81mg dates back to 2005, when Abbott completed the first trial which included 15480 participants. The drug has since been approved and is currently in Phase 4 trials with 168 live studies spanning 57 countries and 1398 cities."

"Individuals aged 18 to 50 are eligible for this trial, with 78 trials targeted at minors and 847 geared towards senior citizens."

"Aspirin 81mg is frequently used as an intervention for percutaneous coronary interventions (PCI), but it also works well to reduce inflammation, neck pain, and even dental procedures."

"This clinical trial is recruiting 60 individuals diagnosed with pre-eclampsia. To be considered eligible, candidates must meet the following requirements: an age of 18-50 years old, a gestational period between 6 0/7 to 13 6/7 weeks gestation, and systolic blood pressure readings ranging from 130-139 mmHg or diastolic levels of 80-89mmHg."

"Affirmative. According to the records hosted on clinicaltrials.gov, this clinical trial is actively seeking candidates; it first appeared online on May 28th 2021 and was last revised on June 25th 2021. This research program requires 60 participants from a single site."

"Based on our team's assessment, Aspirin 81mg received a rating of 3 due to its status as an approved treatment in Phase 4 trials."